Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice

Fuminori Abe, Ibrahim Younos, Sherry Westphal, Holly Samson, Eric Scholar, Alicia Dafferner, Traci A. Hoke, James E. Talmadge

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Mouse mammary tumor virus-Neu (MMTV/neu) transgenic mice on an FVB-background (FVB-neuN) have increased numbers of myeloid derived suppressor cells (MDSCs) and regulatory T-cells (T-regs) in the spleen during mammary tumor induction and progression. Using this transgenic tumor model, we assessed the therapeutic activity of sunitinib, a multi-targeted, tyrosine kinase (TK) inhibitor and its effects on immune-regulatory cells. Our preliminary results show that sunitinib at 40 mg/kg/day, p.o. (per os), delayed the time to tumor induction and reduced the incidence and growth of tumors in FVB-neuN mice. In association with its therapeutic activity, sunitinib reduced the absolute number of splenic T-reg cells (CD4+CD25+CD62L+) and MDSCs (CD11b+Gr1+) that were increased during tumor progression with less activity in mice with gross tumors. A significant decrease in the absolute number of splenic T-regs, dendritic cells (DCs), MDSCs and hematopoietic progenitors (Lin-Sca1+CD90dull) was observed following sunitinib treatment. The frequency of splenic T-regs and hematopoietic progenitors, but not MDSCs was also reduced by sunitinib treatment. Additionally immune-regulatory cytokines and enzymes were down regulated by sunitinib treatment, including TGFβ and NOS2 in the spleen cells of sunitinib treated mice as compared to untreated tumor bearing (TB) mice. We conclude that sunitinib has therapeutic activity, in association with the down regulation of MDSCs and T-regs and has a trend towards the normalization of the inflammatory cytokine levels induced by tumor progression and growth. Based on these results, we suggest that sunitinib reduction of immune suppressive cells is a critical part of its adjuvant immune therapeutic activity.

Original languageEnglish
Pages (from-to)140-145
Number of pages6
JournalInternational Immunopharmacology
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Breast Neoplasms
Neoplasms
Therapeutics
Spleen
Cytokines
Mouse mammary tumor virus
sunitinib
Regulatory T-Lymphocytes
Growth
Protein-Tyrosine Kinases
Dendritic Cells
Transgenic Mice
Down-Regulation
Myeloid-Derived Suppressor Cells
Incidence
Enzymes

Keywords

  • Her2/neu
  • MDSC
  • Sunitinib
  • T-reg
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. / Abe, Fuminori; Younos, Ibrahim; Westphal, Sherry; Samson, Holly; Scholar, Eric; Dafferner, Alicia; Hoke, Traci A.; Talmadge, James E.

In: International Immunopharmacology, Vol. 10, No. 1, 01.2010, p. 140-145.

Research output: Contribution to journalArticle

Abe, F, Younos, I, Westphal, S, Samson, H, Scholar, E, Dafferner, A, Hoke, TA & Talmadge, JE 2010, 'Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice', International Immunopharmacology, vol. 10, no. 1, pp. 140-145. https://doi.org/10.1016/j.intimp.2009.09.023
Abe, Fuminori ; Younos, Ibrahim ; Westphal, Sherry ; Samson, Holly ; Scholar, Eric ; Dafferner, Alicia ; Hoke, Traci A. ; Talmadge, James E. / Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. In: International Immunopharmacology. 2010 ; Vol. 10, No. 1. pp. 140-145.
@article{1ccf0506ab90402b994d74e3e8e96bf8,
title = "Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice",
abstract = "Mouse mammary tumor virus-Neu (MMTV/neu) transgenic mice on an FVB-background (FVB-neuN) have increased numbers of myeloid derived suppressor cells (MDSCs) and regulatory T-cells (T-regs) in the spleen during mammary tumor induction and progression. Using this transgenic tumor model, we assessed the therapeutic activity of sunitinib, a multi-targeted, tyrosine kinase (TK) inhibitor and its effects on immune-regulatory cells. Our preliminary results show that sunitinib at 40 mg/kg/day, p.o. (per os), delayed the time to tumor induction and reduced the incidence and growth of tumors in FVB-neuN mice. In association with its therapeutic activity, sunitinib reduced the absolute number of splenic T-reg cells (CD4+CD25+CD62L+) and MDSCs (CD11b+Gr1+) that were increased during tumor progression with less activity in mice with gross tumors. A significant decrease in the absolute number of splenic T-regs, dendritic cells (DCs), MDSCs and hematopoietic progenitors (Lin-Sca1+CD90dull) was observed following sunitinib treatment. The frequency of splenic T-regs and hematopoietic progenitors, but not MDSCs was also reduced by sunitinib treatment. Additionally immune-regulatory cytokines and enzymes were down regulated by sunitinib treatment, including TGFβ and NOS2 in the spleen cells of sunitinib treated mice as compared to untreated tumor bearing (TB) mice. We conclude that sunitinib has therapeutic activity, in association with the down regulation of MDSCs and T-regs and has a trend towards the normalization of the inflammatory cytokine levels induced by tumor progression and growth. Based on these results, we suggest that sunitinib reduction of immune suppressive cells is a critical part of its adjuvant immune therapeutic activity.",
keywords = "Her2/neu, MDSC, Sunitinib, T-reg, Tyrosine kinase inhibitor",
author = "Fuminori Abe and Ibrahim Younos and Sherry Westphal and Holly Samson and Eric Scholar and Alicia Dafferner and Hoke, {Traci A.} and Talmadge, {James E.}",
year = "2010",
month = "1",
doi = "10.1016/j.intimp.2009.09.023",
language = "English",
volume = "10",
pages = "140--145",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice

AU - Abe, Fuminori

AU - Younos, Ibrahim

AU - Westphal, Sherry

AU - Samson, Holly

AU - Scholar, Eric

AU - Dafferner, Alicia

AU - Hoke, Traci A.

AU - Talmadge, James E.

PY - 2010/1

Y1 - 2010/1

N2 - Mouse mammary tumor virus-Neu (MMTV/neu) transgenic mice on an FVB-background (FVB-neuN) have increased numbers of myeloid derived suppressor cells (MDSCs) and regulatory T-cells (T-regs) in the spleen during mammary tumor induction and progression. Using this transgenic tumor model, we assessed the therapeutic activity of sunitinib, a multi-targeted, tyrosine kinase (TK) inhibitor and its effects on immune-regulatory cells. Our preliminary results show that sunitinib at 40 mg/kg/day, p.o. (per os), delayed the time to tumor induction and reduced the incidence and growth of tumors in FVB-neuN mice. In association with its therapeutic activity, sunitinib reduced the absolute number of splenic T-reg cells (CD4+CD25+CD62L+) and MDSCs (CD11b+Gr1+) that were increased during tumor progression with less activity in mice with gross tumors. A significant decrease in the absolute number of splenic T-regs, dendritic cells (DCs), MDSCs and hematopoietic progenitors (Lin-Sca1+CD90dull) was observed following sunitinib treatment. The frequency of splenic T-regs and hematopoietic progenitors, but not MDSCs was also reduced by sunitinib treatment. Additionally immune-regulatory cytokines and enzymes were down regulated by sunitinib treatment, including TGFβ and NOS2 in the spleen cells of sunitinib treated mice as compared to untreated tumor bearing (TB) mice. We conclude that sunitinib has therapeutic activity, in association with the down regulation of MDSCs and T-regs and has a trend towards the normalization of the inflammatory cytokine levels induced by tumor progression and growth. Based on these results, we suggest that sunitinib reduction of immune suppressive cells is a critical part of its adjuvant immune therapeutic activity.

AB - Mouse mammary tumor virus-Neu (MMTV/neu) transgenic mice on an FVB-background (FVB-neuN) have increased numbers of myeloid derived suppressor cells (MDSCs) and regulatory T-cells (T-regs) in the spleen during mammary tumor induction and progression. Using this transgenic tumor model, we assessed the therapeutic activity of sunitinib, a multi-targeted, tyrosine kinase (TK) inhibitor and its effects on immune-regulatory cells. Our preliminary results show that sunitinib at 40 mg/kg/day, p.o. (per os), delayed the time to tumor induction and reduced the incidence and growth of tumors in FVB-neuN mice. In association with its therapeutic activity, sunitinib reduced the absolute number of splenic T-reg cells (CD4+CD25+CD62L+) and MDSCs (CD11b+Gr1+) that were increased during tumor progression with less activity in mice with gross tumors. A significant decrease in the absolute number of splenic T-regs, dendritic cells (DCs), MDSCs and hematopoietic progenitors (Lin-Sca1+CD90dull) was observed following sunitinib treatment. The frequency of splenic T-regs and hematopoietic progenitors, but not MDSCs was also reduced by sunitinib treatment. Additionally immune-regulatory cytokines and enzymes were down regulated by sunitinib treatment, including TGFβ and NOS2 in the spleen cells of sunitinib treated mice as compared to untreated tumor bearing (TB) mice. We conclude that sunitinib has therapeutic activity, in association with the down regulation of MDSCs and T-regs and has a trend towards the normalization of the inflammatory cytokine levels induced by tumor progression and growth. Based on these results, we suggest that sunitinib reduction of immune suppressive cells is a critical part of its adjuvant immune therapeutic activity.

KW - Her2/neu

KW - MDSC

KW - Sunitinib

KW - T-reg

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=73149103231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149103231&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2009.09.023

DO - 10.1016/j.intimp.2009.09.023

M3 - Article

VL - 10

SP - 140

EP - 145

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 1

ER -